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Abstract
Background: There is an increased risk of serious neonatal infection arising through exposure of the umbilical cord
to invasive pathogen in home and facility births where hygienic practices are difficult to achieve. The World Health
Organization currently recommends ‘dry cord care’ because of insufficient data in favor of or against topical
application of an antiseptic. The primary objective of this meta-analysis is to evaluate the effects of application of
chlorhexidine (CHX) to the umbilical cord to children born in low income countries on cord infection (omphalitis)
and neonatal mortality. Standardized guidelines of Child Health Epidemiology Reference Group (CHERG) were
followed to generate estimates of effectiveness of topical chlorhexidine application to umbilical cord for prevention
of sepsis specific mortality, for inclusion in the Lives Saved Tool (LiST).
Methods: Systematic review and meta-analysis. Data sources included Cochrane Central Register of Controlled
Trials (CENTRAL) in the Cochrane Library, PubMed, CINHAL and WHO international clinical trials registry. Only
randomized trials were included. Studies of children in hospital settings were excluded. The comparison group
received no application to the umbilical cord (dry cord care), no intervention, or a non-CHX intervention. Primary
outcomes were omphalitis and all-cause neonatal mortality.
Results: There were three cluster-randomised community trials (total participants 54,624) conducted in Nepal,
Bangladesh and Pakistan that assessed impact of CHX application to the newborn umbilical cord for prevention of
cord infection and mortality. Application of any CHX to the umbilical cord of the newborn led to a 23% reduction
in all-cause neonatal mortality in the intervention group compared to control [RR 0.77, 95 % CI 0.63, 0.94; random
effects model, I2=50 %]. The reduction in omphalitis ranged from 27 % to 56 % compared to control group
depending on severity of infection. Based on CHERG rules, effect size for all-cause mortality was used for inclusion
to LiST model as a proxy for sepsis specific mortality.
Conclusions: Application of CHX to newborn umbilical cord can significantly reduce incidence of umbilical cord
infection and all-cause mortality among home births in community settings. This inexpensive and simple
intervention can save a significant number of newborn lives in developing countries.
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Introduction
Since 1998, the World Health Organization has recom-
mended promotion of clean and dry cord care for new-
born infants, while noting that topical antiseptics may be
used where risk of infections is high [1]. A Cochrane
review by Zupan et al included 21 trials involving 8959
subjects and covered all types of antiseptics applied to
umbilical cord [2]. All of the included studies were con-
ducted in hospital settings and, with the exception of one
trial from Thailand, in high income countries. There were
no systemic infections or deaths, the primary outcomes
considered by the review, in any of the trials. Risk of umbi-
lical cord infection was approximately half as likely when a
topical antiseptic was applied, as compared with dry cord
care or placebo, but the combined result did not reach sta-
tistical significance (RR = 0.53; 95% CI 0.35 –1.13). Topical
triple dye seemed to be more effective than alcohol (RR=
0.30; 95% CI: 0.19–0.49) or povidone-iodine (RR = 0.15,
95% CI: 0.07–0.32) in preventing cord infection, however
no specific recommendations were made in favor or
against of an antiseptic, as the overall evidence was
inconclusive.
While umbilical cord infections can occur in all settings,
they are more likely to occur in low-income countries,
where the majority of births take place at home in unclean
settings and are not attended by a skilled attendant [3].
Since all but one of the aforementioned trials were con-
ducted in hospitals in high income countries, the results
cannot be generalized to community settings in low
income countries where achieving clean and dry cord care
is difficult in general [4,5].
Recently, three large community-based randomized
trials have been conducted in Nepal, Bangladesh and
Pakistan to study the effectiveness of application of
4.0% chlorhexidine (CHX) to the umbilical cord after
birth. The objective of this study was to undertake a meta-
analysis of these studies to evaluate the effect of application
of chlorhexidine to the umbilical cord for prevention of
omphalitis and neonatal mortality in community settings.
This paper is a part of series of papers for Lives Saved Tool
(LiST) model which is a computer-based model that esti-
mates the impact of increasing coverage of different inter-
vention packages and coverage levels for individual
countries, states or districts [6]. The ultimate goal of LiST
tool is to provide a structured format for program managers
or ministry of health personnel to combine the best scienti-
fic information about effectiveness of interventions for
maternal, neonatal and child health with information about
cause of death and current coverage of interventions to
inform their planning and decision-making, to help priori-
tize investments and evaluate existing programs. An inter-
vention is currently included in the LiST if there is
substantial evidence that it decreases maternal mortality,
neonatal/child mortality and/or stillbirths. The process of
inclusion of a particular intervention to LiST tool is guided
by qualitative assessment of available evidence according to
Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) criteria and quantitative inputs
according to Child Health Epidemiology Reference Group
(CHERG) guidelines [6,7].
Methods
Literature search
We searched the Cochrane Central Register of Con-
trolled Trials, PubMed and CINHAL. All searches were
conducted on November 22, 2012. We used the follow-
ing search strategy on PubMed: (“Chlorhexidine”[Mesh]
OR Chlorhexidine* AND “Umbilical Cord”[Mesh]) OR
“Umbilicus”[Mesh]). No limits were applied to this
search strategy. To identify ongoing and unpublished
trials, we used the WHO international clinical trials reg-
istry, which searches multiple trial registries. Reference
lists of reviews, included studies, and excluded studies
were also searched for additional citations. We con-
tacted organizations and researchers by email and by
phone to obtain additional data if required.
Eligibility criteria
Types of trials
Community randomized controlled trials including clus-
ter trials and factorial trials were included irrespective of
publication status or language.
Types of participants
Neonates born alive to women enrolled in the study.
Studies conducted entirely in hospital settings were
excluded.
Types of interventions
Included studies examined effectiveness of topical appli-
cation of 4.0 % chlorhexidine to newborn umbilical cord
for prevention of omphalitis and neonatal mortality. The
comparison group received dry cord care, no interven-
tion or non CHX intervention.
Types of outcome measures
The primary outcomes were incidence of sepsis-specific
mortality, all-cause mortality and omphalitis in the neo-
natal period. Neonatal period was defined as first
28 days of life. We also examined cord separation time
in the intervention group compared to control. For the
outcome omphalitis, three case definitions were used:
• Algorithm 1: Moderate or severe redness
• Algorithm 2: Moderate redness with pus, or severe
redness (without regard to pus)
• Algorithm 3: Severe redness with pus
Data abstraction and risk of bias assessment
All the included trials were assessed for methodological
quality and outcomes of interest using a standardized
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form [7]. Two reviewers (AI and ZAB) independently
assessed the studies for inclusion. Data were double
abstracted. Data were abstracted for study design, study
site, study methods and outcomes of interest. Risk of bias
in the included studies was assessed with the Cochrane
Collaboration’s risk of bias tool [8]. This assessment is
based on five criteria that includes bias from sequence
generation, allocation concealment, blinding of partici-
pants, assessors, and providers, selective outcome report-
ing and incomplete data. Risk of bias for each domain is
rated as high (seriously weakens confidence in the results),
low (unlikely to seriously alter the results), or unclear.
Individual studies were graded according to CHERG
adaptation of GRADE technique. In this method of quali-
tative evaluation, all randomized trial received an initial
score of ‘high’ and an observational study as ‘low’. The
study scores were adjusted depending on limitations of the
study design. Trials with a final grade of ‘high’ or ‘moder-
ate’ and ‘low grade’ were included in the analysis with
exclusion of studies with a final grade of ‘very low’ [7].
Quantitative data synthesis
Meta-analyses were conducted where data were available
from more than one study for an outcome. The results
were presented as risk ratios (RR) and 95% confidence
intervals (CIs). Random effects meta-analysis was used for
all analyses. For cluster randomized trials, we used the
reported cluster-adjusted risk ratio and 95% confidence
interval, irrespective of the method used [9]. The value of
design effect was taken as stated in the study or was
inferred from intra-cluster correlation coefficient. Pooled
estimates of the evaluated outcome measures were calcu-
lated by the generic inverse variance method. This method
is a common and simple version of the meta-analysis pro-
cedure and is so named because the weight given to each
study is chosen to be the inverse of the variance of the
effect estimate (i.e. one over the square of its standard
error) [9]. In this way larger studies, which have smaller
standard errors, are given more weight than smaller stu-
dies, which have larger standard errors. This minimizes
the imprecision (uncertainty) of the pooled effect estimate.
The assessment of statistical heterogeneity among trials
was done by visual inspection i.e. the overlap of the confi-
dence intervals among the studies, Chi square (P-value) of
heterogeneity in the meta-analyses and I2 value. A low
P value (less than 0.10) or a large I2 statistic (I2 >50 %) was
considered as evidence of significant heterogeneity, which
was explored further by sensitivity analysis as required. All
meta-analyses were conducted using software Review
Manager version 5.1 [10]. Qualitative assessment of pooled
data was presented in “Summary of findings” table accord-
ing to the Child Health Epidemiology Group (CHERG)
adaptation of the GRADE criteria [7].
The three included studies comprised 10 study groups.
In order to obtain a summary effect estimate from all
the CHX groups, we combined the groups as shown in
table 1. This approach was adopted based on expert opi-
nion canvassed at a meeting held at John Hopkins Uni-
versity in January 2010 and further sensitivity analysis
was undertaken to explore possible bias.
Recommendations for LiST
We followed standardized guidelines of Child Health Epi-
demiology Reference Group to get a point estimate for
effectiveness of application of chlorhexidine to the umbili-
cal cord for prevention of sepsis-specific neonatal mortal-
ity in community settings. These rules were applied to
collective mortality and morbidity outcomes to get a most
appropriate estimate for inclusion in the LiST model. The
final decision about the best estimate is based on three
components 1) the volume and consistency of the evi-
dence 2) the size of risk ratio and 3) the strength of the
statistical evidence for an association between the inter-
vention and outcome, as reflected by the p-value. More
details about application of CHERG rules are provided in
the methods paper [7].
Results
Trial flow
The literature search of electronic databases, and papers
from hand searches yielded a total of 2303 titles after
removal of duplicates (Fig 1). After initial screening of
titles and abstracts, 10 studies were selected for data
abstraction. Of these 7 were excluded because they were
hospital-based studies (n=5), or compared two different
forms of CHX (n=1) or both groups had received antisep-
tics (n=1). The three included trials were conducted in
Nepal, Bangladesh, and Pakistan [11-13]. A search of
WHO’s international clinical trials registry and commu-
nication with investigators in the field revealed two
ongoing community-based randomized trials, one in
Tanzania [14] and one in Zambia [15].
Study characteristics
Table 2 describes the characteristics of included studies.
All three included studies from Nepal, Bangladesh and
Pakistan were cluster randomized community trials. The
total number of participants in the three trials was
54,624. Duration of follow up in all the studies was the
first 28 days of life except in the Pakistan trial where a 6
month follow up visit was also made. The overall dura-
tion of CHX application in CHX intervention groups
(A & C) were 11.1 ± 2.8 days with a mean 2.4 ± 0.7 appli-
cations per/day in Pakistan trial [13]. In Bangladesh and
Nepal trials, all babies were enrolled if alive at the first
home visit by project staff, and the first visit took place
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within 7 (Bangladesh) and 10 (Nepal) days after birth. In
Pakistan, babies who were live born and delivered by par-
ticipating TBAs were enrolled. In the Bangladesh trial,
high intervention coverage was achieved for enrolled
newborns and less than 1% of the participants received
no intervention visit [12]. Both the Nepal and Bangladesh
trials included hospital born babies. The average number
of home visits per newborn was 6.5 out of 7 and 84.0% of
the enrolled newborns received the complete 7 days of
intervention [12]. In the Pakistan trial, about 97% of
enrolled infants received at least one CHX application. In
the Nepal trial, effective coverage was about 96.3 % and
the average number of home visits was 5.9 ± 1.5 days out
of 7 days [11]. Additional file 1 summarises the risk of
bias in included studies according to latest Cochrane
handbook [8].
Table 1 Scheme of analysis for chlorhexidine groups and non-chlorhexidine groups in the included studies
Study ID Study groups Any CHX vs. No CHX
Nepal trial 2006 [11] Group A: Multiple cleansing of cord stump with 4 % CHX.
Group B: Cleansing of cord with Soap and water
Group C: Dry cord care
Group A vs. Group B +C
Bangladesh trial
2012 [12]
Group A: Multiple cleansing of cord stump with 4 % CHX.
Group B: Single cleansing of cord stump with 4 % CHX.
Group C: Dry cord care
Group A + B vs. Group C
Pakistan trial 2012
[13]
Group A: Multiple cleansing of cord stump with 4 % CHX and promotion of
handwashing among caregivers.
Group B: Promotion of handwashing only.
Group C: Multiple cleansing of cord stump with 4 % CHX only
Group D: Dry cord care
Group A +C vs. Group B +D
CHX: Chlorhexidine
Figure 1 Flow diagram showing identification of studies
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Quantitative data synthesis
Effect on sepsis specific mortality
The Nepal trial reported data on sepsis-specific mortal-
ity and reported a 31 % reduction in CHX group com-
pared to dry cord care however the results were not
statistically significant (RR=0.69, 95 % CI 0.40-1.18) [11].
The overall quality grade for this outcome was that of
“low” level (Table 3).
Effect on all-cause mortality
There were 1325 deaths in all study groups and the
combined results for “any CHX vs. No CHX” showed an
important reduction of 23% in all-cause neonatal mor-
tality (RR = 0.77, 95 % CI 0.63 - 0.94; random model,
I2=50 %] (Fig 2). The quality of the evidence was graded
as ‘moderate’ for this outcome (Table 3). When restrict-
ing analysis to facility births only (available from Nepal
and Bangladesh) there was no indication that the impact
of chlorhexidine was lessened (RR=0.50 [0.27 - 0.92]).
Omphalitis
Data for omphalitis were analyzed according to three
different algorithms used to define omphalitis. Figure 3
shows the meta analytic results. CHX was associated
with reductions in omphalitis using all three algorithms
with the largest reduction observed for severe omphalitis
(RR = 0.46, 95 % CI 0.32-0.66). The quality of the evi-
dence was graded as ‘moderate” for mild omphalitis and
‘high’ that for moderate and severe omphalitis.
Cord separation time
In the Nepal trial, cord separation time was longer in the
CHX group (5.32 ± 2.4 days) compared to the dry cord
care group (4.24 ± 1.6 days). In the Pakistan trial, there
was no difference in the time to separation of the cord
between each group [CHX group 6.2 ± 1.3 days, group
HW 5.9 ± 1.5, groups CHX + HW and dry cord care
both 6.0 ± 1.6 days]. In Bangladesh, separation time in
the combined chlorhexidine group (7.20 ± 3.0 days) was
2.40 (95% CI: 2.17 – 2.64) days longer than among babies
not exposed to chlorhexidine (4.79 ± 1.8 days).
Application of CHERG rules
We followed standardized guidelines of Child Health Epi-
demiology Reference Group to get a point estimate for
effectiveness of chlorhexidine application of chlorhexidine
Table 2 Characteristics of included studies
Study characteristics Nepal trial* Bangladesh trial Pakistan trial
Type of study Cluster RCT Cluster RCT 2 × 2 factorial design cluster RCT
No. clusters (average
size)
413 (700) 133 (4100) 187 (1000)
Sample size total 15,123 29,760 9,741
Average sample size per
group
~ 5,050 ~ 9,900 ~ 4,850
Duration of trial Nov 2002 to Mar 2005 Jun 2007 to Sep 2009 Jan 2008 to Jun 2009
Overall NMR 32/1000 36/1000 30/1000
% of home births 92 % 93 % 80 %
Inclusion criteria All live births in the
study area
All live births in the study area All live births in the study area were included except
those who were born in hospitals.
Exclusion criteria Not met within 10 days
after birth
Didn’t receive intervention within 7
days after birth
Not met within 3 days after birth. Babies with
congenital anomalies
Comparison group Dry cord care Dry cord care Dry cord care
Intervention groups 1.Multiple CHX
2.Soap/H2O
1.Multiple CHX
2.Single CHX
1.Multiple CHX
2.Handwashing (HW)
3.CHX + HW
CHX concentration 4.0 % 4.0 % 4.0 %
Participants recruiters Local female worker CHWs CHWs
Intervention providers Local project staff Village health worker TBA to caretaker
Outcome assessors (Nonmedical) field
workers
CHWs CHWs
Basic interventions to all
babies/mothers
CDK, FE/FA, TT,
promotion of ANC/ENC
CDK. FE/FA, promotion of TT, ANC,
birth preparedness, ENC
Basic component of ENC as promoted by Ministry of
Health
Primary outcomes Omphalitis, neonatal
mortality
Omphalitis, neonatal mortality Omphalitis, neonatal mortality
Follow up days 1, 2, 3, 4, 6, 8, 10, 12, 14,
21, 28
1,3,6,9,15,28 1,3,5,7,14,28
RCT: Randomized Controlled trial, CHX: chlorhexidine, CDK: clean delivery kit, Fe/FA: Iron/Folic acid, TT, Tetanus oxide, ANC: Antenatal care, ENC: essential
newborn care, CHW: Community Health Workers, TBA: Traditional Birth Attendant
* Nepal trial was nested within a study of the effect of full-body skin cleansing with antiseptic on neonatal mortality. In that trial, newborns were given a single
fullbody wipe with either 0·25% chlorhexidine or placebo solution immediately after birth. In each skin cleansing group (0·25% chlorhexidine or placebo) in the
main trial, sectors were randomized to one of three cord-care regimens (Which makes total of 6 study groups).
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Table 3 Summary of findings of trials to assess the effect of application of CHX to newborn’s umbilical cord
Quality Assessment Summary of findings
Generalizability Number of cases Pooled
effect
No. of
studies
Design Limitations Consistency Generalizability
to Population
of Interest
Generalizability to intervention of
Interest
CHX Control Relative
risk (95
% CI)
Sepsis Specific mortality: GRADE quality: Low
1 RCT None Only one trial reported data All the
participants
were neonates
4.0% chlorhexidine solution. Only RR was reported in the published
manuscript.
0.69
(0.40-
1.18)
All-Cause neonatal mortality: GRADE quality: Moderate
3 RCT All three included studies are well
conducted community randomized
trials. Intervention was not masked
in two studies.
Direction of effect in favor of
intervention in all three studies.
There was moderate statistical
heterogeneity (I2 =50%).
All the
participants
were neonates
All the studies used 4.0%
chlorhexidine solution. Frequency
of application was different in
different study groups.
670/29543 655/25072 0.77
(0.63-
0.94)
Incidence of omphalitis: Algorithm 1 GRADE quality: Moderate
3 RCT All three included studies are well
conducted community randomized
trials. Intervention was not masked
in two studies.
Direction of effect in favor of
intervention in all three studies.
There was moderate statistical
heterogeneity (I2 =34%).
All the
participants
were neonates
All the studies used 4.0%
chlorhexidine solution. Frequency
of application was different in
different study groups.
Not applicable as
data was pooled
by generic inverse
variance
Not applicable as
data was pooled
by generic inverse
variance
0.73
(0.64-
00.83)
Incidence of omphalitis: Algorithm 2 GRADE quality: High
3 RCT All three included studies are well
conducted community randomized
trials. Intervention was not masked
in two studies.
Direction of effect in favor of
intervention in all three studies. No
statistical heterogeneity (I2 =0%).
All the
participants
were neonates
All the studies used 4.0%
chlorhexidine solution. Frequency
of application was different in
different study groups.
Not applicable as
data was pooled
by generic inverse
variance
Not applicable as
data was pooled
by generic inverse
variance
0.69
(0.60-
0.79)
Incidence of omphalitis: Algorithm 3 GRADE quality: High
3 RCT All three included studies are well
conducted community randomized
trials. Intervention was not masked
in two studies.
Direction of effect in favor of
intervention in all three studies.
Small statistical heterogeneity (I2
=19 %).
All the
participants
were neonates
All the studies used 4.0%
chlorhexidine solution. Frequency
of application was different in
different study groups.
Not applicable as
data was pooled
by generic inverse
variance
Not applicable as
data was pooled
by generic inverse
variance
0.46
(0.32-
0.66)
• The GRADE assessment is based on
1) The volume and consistency of the evidence.
2) The size of summary estimate and
3) The strength of the statistical evidence for an association between the intervention and outcome.
• The quality grade can be interpreted as follows:
High quality— Further research is very unlikely to change our confidence in the estimate of effect
Moderate quality— Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate
Low quality— Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
Very low quality— Any estimate of effect is very uncertain
• This GRADE table is an adaptation form CHERG methods paper[7] and GRADE paper[26]
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Figure 2 Effect of chlorhexidine cord cleansing on all-cause neonatal mortality
Figure 3 Effect of chlorhexidine application to newborn’s umbilical cord. Any Chlorhexidine vs. No Chlorhexidine: Incidence of Omphalitis
according to severity. Algorithm 1: Redness extending to skin. Algorithm 2: Redness with Pus, or Severe Redness. Algorithm 3: Severe Redness
with Pus
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to the umbilical cord for prevention of sepsis-specific neo-
natal mortality in community settings. Table 4 gives the
details of application of CHERG rules. Estimate for all-
cause mortality was recommended to be included to LiST
model.
Discussion
The results of this meta-analysis indicate that applica-
tion of CHX to the newborn umbilical cord substantially
reduced all-cause neonatal mortality and omphalitis in 3
low resource settings in Asia. All-cause mortality among
newborns was reduced by 23% in the CHX group com-
pared to controls. The reduction in incidence of ompha-
litis ranged from 27% to 54% depending on the severity
of infection.
Strengths and limitation
This meta-analysis evaluates the effect of umbilical cord
cleansing by CHX aqueous solution on neonatal mortal-
ity and omphalitis in community settings. Another
recently published review of chlorhexidine trial reported
similar findings [16]. For the primary outcome, neonatal
mortality, the evidence is striking. Three studies com-
prising 10 study groups involving 54,624 participants
were analyzed. All the studies reported a protective
effect in favor of umbilical cord cleansing by CHX to
prevent neonatal death. The quality of the evidence was
graded as “moderate” on the GRADE scale (table 3). All
studies were randomised with appropriate methods for
sequence generation and the study and control groups
were comparable in all studies. It was not feasible to
mask the intervention for participants and providers, so
masking was not done in two studies. Failure to mask
and missing data are unlikely to have biased the results
as attrition was balanced. Risks of selective outcome
reporting were low as protocols of studies were available
for evaluation of reporting of a priori outcomes. An
important observation is that all the babies born in the
study period of three studies were not included in the
analysis as they could not be enrolled. For example in
Bangladesh trial there were 770 deaths among enrolled
children but 397 children died before they were
enrolled. So the effect estimate is not the effect on all
neonatal deaths during the study period. In case all the
neonatal deaths were accounted in the study period,
effect size might have become smaller. This analysis
however requires the assumption that the CHX would
have no effect on babies that did not receive interven-
tion, which may not be true. Another important limita-
tion of the current analysis is that we did not have
segregated data for low birth weight and premature
babies. It is well known that risk of sepsis is greater in
preterm and low birth weight babies [17] and their pre-
valence may differ in different parts of the world. It is
therefore not well established that if CHX had any dif-
ferential effect for prevention of mortality in low birth
weight or preterm babies.
Study populations in Nepal, Bangladesh and Pakistan
were representative of much of the population in South-
east Asia. This implies that the intervention can at least
be applied to Southeast Asian region that contribute a
significant number of neonatal deaths around the globe
[18]. There are no data available from Africa yet how-
ever two randomized trial are being conducted there
that will further strengthen the evidence in favor or
against of the intervention. No immediate side effects
were reported in any of the studies. One important con-
sideration is the reported increase in cord separation
time. In the Nepal and Bangladesh studies, participants
in CHX group had longer cord separation time com-
pared to the controls [19]. In both studies however,
there was no additional risk of infection associated with
increases in cord separation time. There was no differ-
ence in cord separation time in Pakistan trial [13].
Choice of comparisons
The three included studies had 10 study groups that
tested different frequency and duration of CHX applica-
tion. The comparison groups included dry cord care
[11-13], washing of cord with soap/water [11] and
Table 4 Application of CHERG Rules for selection of point estimate for sepsis mortality for inclusion to LiST model [7]
Outcome
measure
Studies Total
Events
Effect size GRADE quality
of pooled
estimate
Application of standard rules
Sepsis specific
neonatal
mortality
(n=1) Not
reported
31 % reduction,
statistically non-
significant
(RR=0.69, 95 % CI
0.40-1.18)
Low Effect size for sepsis specific mortality was not used for inclusion in
LiST model as results were not statistically significant and overall
quality grade was “low”
All cause
neonatal
mortality
(n=3) 838 23% reduction,
Statistically
significant
(RR=0.77, 95 % CI
0.63 - 0.94)
Moderate ®
Low
Effect size for all-cause mortality was used for inclusion to LiST model.
This was based on rule 1 that says that if there is no evidence for
cause specific mortality and there is evidence for all-cause mortality,
use the effect size for all-cause and down grade quality grade by
one.
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promotion of handwashing practices of caregivers [13].
In order to examine whether CHX has any protective
effect compared to these comparison groups, all the
CHX groups were combined and all the other groups
compared in an analysis “any CHX vs. no CHX” as
shown in table 1. This combination of study groups are
not expected to bias the results as the soap/water group
in Nepal study had an effect size very similar to control
(i.e. dry cord care). The Pakistan trial was a factorial
design trial and we included the factorial analyses in
which handwashing groups were balanced between the
two study groups (CHX + HW and CHX only versus
HW only and Dry cord care). The Bangladesh trial had
two CHX groups i.e. 1 day or 7 day application. These
were combined to include CHX groups in one arm and
compared it with all non-CHX interventions across
three studies.
Choice of model
We used random effects meta-analysis for all analyses.
There are no comprehensive rules on when to use ran-
dom effects or fixed effects models for meta-analysis [8].
The difference between two models is that a fixed
effects model assumes that observed differences between
results of trials is due to sampling variation of individual
studies only whereas a random effects model assumes
that outcomes of trials might differ both because of
sampling variation of individual studies and true diver-
sity in effects. Both models can be appropriately applied
for pooling data but a random effects model is usually
preferred with heterogeneity. We used random effects
models because there was substantial heterogeneity
across studies in study design, settings, and package of
interventions and/or intensity of delivery of those inter-
ventions. Another reason to use random model was that
we assumed that the true effect of CHX does vary
across the community settings based on above factors.
Predictors of statistical heterogeneity
For all-cause mortality, there was moderate statistical
heterogeneity (I2=50%). One of the likely causes of this
heterogeneity was the difference in mortality rates
among enrolled babies in the control populations. The
mortality in the control group was 36.1/1000 in Pakistan
trial, 28.3/1000 in Bangladesh trial and 19.3/1000 in
Nepal trial. Other important factors to consider are the
home practices for cord care in different communities.
For example, in the Pakistan trial, a significant propor-
tion of study population applied lead (called surma in
the local language) to the umbilical cord stump, which
may cause irritation at the site and provide a port of
entry for infectious agents. Other practices across the
studies included application of materials such as ash,
mud and even cow dung; however their prevalence was
very low. It is important to note that these home prac-
tices may increase the risk of cord infections but do not
explain the overall increased rate of high cord infections
in these communities. Furthermore, as the most egre-
gious of these practices are rare, it should not be
assumed that this type of traditional practice is the
major source of exposure of the cord stump to invasive
pathogens. The large reductions in mortality and
omphalitis in the chlorhexidine groups suggest that cord
exposure to pathogens is high due to more ubiquitous
barriers to achieving hygienic conditions. Examination
of the bacteriological profile of the stump of a subset of
newborns from the Bangladesh trial (where traditional
application to the cord were rarely reported) demon-
strated that colonization of the cord with potentially
invasive pathogens such as E. Coli, K. Pneumonia, S.aur-
eous, and streptococcus spp is widespread and substan-
tially reduced through chlorhexidine [20].
Safety of the intervention
Cleansing of the umbilical cord with CHX is considered
safe [21,22]. CHX is a broad spectrum antiseptic exten-
sively used in dental, obstetric and surgical scrubs. It
has also been used in obstetrics, peri-partum, perineal
and vaginal washes in concentrations as high as 4% [23].
CHX is currently included in WHO’s Essential Drugs
List and is the antiseptic of choice for cord care in hos-
pitals [17]. Despite widespread use in clinical and com-
munity settings for over 30 years, no significant adverse
events associated with topical applications to the cord
stump have been reported in neonates [22]. No side
effects were reported in any of the included studies in
this review.
Implications for policy
Infections contribute to about one third of 3 million
annual neonatal deaths in developing countries [18].
The risk of infection is significantly high in the case of
home deliveries, often attended by unskilled traditional
birth attendants with unclean delivery practices [24] and
potentially harmful family practices for cord care [4].
The widespread application of harmful substances to the
cord stump, seen in many poor urban and rural settings,
can facilitate the entrance of microorganisms and skin
flora into blood stream leading to infection and ompha-
litis [5]. Compounding these problems are high rates of
low-birth-weight and preterm birth, often associated with
increased risk of infections [25]. This review makes an
important contribution by identifying an intervention for
appropriate umbilical cord care in community settings in
developing countries, and suggests that application of 4%
CHX to newborn umbilical cord can substantially reduce
cord infection and neonatal mortality. According to
CHERG rules, an estimate for all-cause mortality was
Imdad et al. BMC Public Health 2013, 13(Suppl 3):S15
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used for inclusion to LiST model for sepsis mortality.
This was due to the fact that there was not enough data
for sepsis specific mortality and the overall quality of
data was “low”. Based on CHERG method paper, estimate
for all-cause mortality (i.e. 23 % reduction) was used by
downgrading overall quality assessment from “moderate”
to “Low”. We believe that this simple and inexpensive
intervention, if applied at scale, has the potential to sig-
nificantly reduce neonatal mortality in developing
countries.
Conclusions and implications for future research
Application of 4% CHX to umbilical cord of newborn
leads to a reduction of 23% (95% CI: 6 % to 37%, ran-
dom effect model) in all-cause neonatal mortality com-
pared no CHX. Application of CHX leads to reduction
in omphalitis in a range of 27% to 56% compared to
controls depending on severity of infection. The most
prominent protective effects of CHX occur in first week
of life. The impact decreases after first week of life, but
remains significant throughout neonatal period.
All three included studies were conducted in South Asia
and one included a delivery strategy using birth kits and
usage by family members. Further studies are being con-
ducted in community settings in Africa to assess the inter-
vention and potentially replicate findings [14,15]. Once
available, those data should also inform the global evi-
dence-base. Future studies should also evaluate delivery
methods of CHX in large community programs. Neverthe-
less, this meta-analysis provides promising information of
relevance to policies for newborn care in South Asia, espe-
cially among home births and high-risk situations and
calls into question the current WHO recommendations
for dry cord care in all settings. Finally, the protective ben-
efit of chlorhexidine appeared to be similar among facility-
born and home-born babies. This finding is not surprising
given the challenges of achieving hygienic practices in
facilities during labor, delivery and the immediate postpar-
tum period, and the fact that in the vast majority of cases
facility-born babies are very quickly discharged into the
same conditions as home-born babies.
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